Completed in two stages, the plant has begun operating fourteen 2,000 liter disposable bioreactors for fed-batch cell culture in the facility.
December 7, 2017 -- Wuxi Biologics has completed construction of its $150 million 30,000 liter biomanufacturing facility in China. The CRO/CMO initially announced it would build the facility in April 2015. Completed in two stages, the plant has begun operating fourteen 2,000 liter disposable bioreactors for fed-batch cell culture in the facility, the second construction phase, greatly expanding Phase I capacity, which consisted of two 1000 liter disposable bioreactors. WuXi Biologics’ plant, located in Wuxi city offers cGMP contract manufacturing services for biologic drugs to WuXi clients.
